sampleID ptInitials collDate mutation Patient.initials Gender Age.at.Nil.Das.start..yrs. Imatinib.resistant..intolerant Disease.Phase X2TKI.therapy Date.of.First.Nilotinib.Dasatinib.Imatinib Follow.up..months. Response.at.end.of.study.or.last.sample.received Achieved.a.CCyR. Mo.of.CCyR. Mutation.at.start.of.Nilotinib.Dasatinib.by.Direct.Sequencing X..Mutations.by.Direct.Sequencing.at.start.of.Nil.Das Mutations.detected.by.MassArray.at.start.of.Nilotinib.Dasatinib.in.replicate.samples X..Mutations.detected.by.MassArray.at.start.of.Nil.Das new.mutations.that.emerged.during.nilotinib.or.dasatinib.therapy..OR.Imatinib.for.IC...MT. Month.of.1st.new.mutation Group.4.Sample.Notes.if.Applicable 1 JJB 15/9/05 e255v:58.05,t315i:8.64,e355g:7.79,m244v:6.39,e255k:5.86,g250e:1.72,e255*:1.48,q252h:1.2,a433p:0.67,e352g:0.6,n358s:0.52,e238e:0.49,e409g:0.35 JJB M 29 resistant CP nilotinib 38610 15 failure - no cyto resp 3m NA M244V 5%, E255V 60% T315I 15% 3 E255V E355G M244V G250E Q252H(G>C) T315I E255K 7 NA 2 LAJ 1/6/05 m351t:90.62,h396r:2.88,f486s:2.5,e255v:1.41,g249d:1.23,e459k:1.2,e279k:0.83,r460c:0.79,m496v:0.67,t495a:0.64,e488e:0.57,n368s:0.57,l284l:0.56,k291e:0.55,n374d:0.53,e470g:0.46,e238e:0.46,g227g:0.44,k262r:0.39,d363d:0.38,l364p:0.38,k294r:0.37,l327l:0.36 LAJ F 62.6082191780822 resistant CP dasatinib 38504 10 progression NA M351T 90%, H396R 5% 2 E255V M351T H396R F486S F359V G250E L248V E459K 8 F317L (949T>C, 951 C>G, 951C>A) 6 3 CAN 27/6/05 m244v:66.11,l248v:16.47,g250e:5.99,e355g:1.27,m351t:1.17,g249d:1.1,y253h:1.08,t495a:0.69,k247e:0.61,k294e:0.54,e470g:0.49,f486s:0.4 CAN F 21.5643835616438 resistant CP dasatinib 38530 12 lost CCyR - toxicity Y 6 M244V 75%, L248V 35% 2 M351T Y253H E355G M244V G250E L248V 6 NA 4 GC 5/7/05 g250e:97.79,w235r:3.75,m244v:2.21,t240m:1.22,n322n:0.87,r460r:0.75,t389t:0.74,v270v:0.68,d363y:0.6,t240a:0.46,m343t:0.46,k291k:0.45,t495a:0.44,k291e:0.43,l471f:0.41,v228a:0.36,n331s:0.36,m318v:0.35,y257c:0.34,n336s:0.32,e292g:0.31,q300r:0.31,r328t:0.3,n336d:0.3,e329g:0.29,n322d:0.27,m351t:0.26,n358s:0.25,h490r:0.23,t315i:0.01 GC M 61.7013698630137 resistant CP dasatinib 38538 29 lost CCyR Y 3 G250E 100%, M244V 5% 2 M244V G250E 2 NA 5 KM 5/7/05 e255k:90.52,g250e:17.92,g321g:0.76,k291k:0.75,k404k:0.63,v228a:0.63,e494e:0.6,t495a:0.56,e470e:0.53,n336s:0.52,e352g:0.51,f359l:0.49,e286g:0.48,l341p:0.46,t394t:0.46,k294e:0.44,k454r:0.41,f486s:0.38 KM M 54.4109589041096 resistant CP dasatinib 38538 24 CCyR Y 3 G250E 20%, E255K 100% 2 G250E E255K 2 NA 6 EAD 5/1/06 e255k:75.85,g250e:17.85,e255v:6.37,h396r:2.76,d482d:1.11,e255*:1.04,e459k:1,g249d:0.97,v304i:0.91,k262r:0.8,e334e:0.78,t495a:0.77,r483l:0.64,y440h:0.61,l411l:0.58,e255m:0.56,v260v:0.48,r473r:0.4,e292g:0.37,e352d:0.32,h490r:0.25 EAD 30 resistant AP nilotinib 38722 6 no MCyR NA G250E 15%, E255K 70% 2 E255V H396R G250E E459K E255K 5 E255V 6 7 CHL 26/4/06 q252h:67.48,f359v:12.93,k294k:0.96,t277s:0.9,m244v:0.75,t495a:0.51,n336d:0.48,n336s:0.48,k291k:0.4,e462e:0.38,d455g:0.31,e470e:0.27,k454e:0.25 CHL 52 resistant AP nilotinib 38833 12 no MCyR NA Q252H (G>C) 70%, D276G 20%, 829 T>A 20%, F359V 5% 4 F359V Q252H(G>C) *D276G not detected due to T277S on same clone 2 F359V 1 8 NA NA NA CL 73 resistant AP nilotinib 38874 6 no MCyR NA E255K 85%, 1189G>C 15% 2 E255K 1 NA 9 VV 7/3/05 h396r:84.62,a397p:36.91,m244v:9,e450g:3.18,g321g:2.08 VV F 74.7561643835616 resistant AP dasatinib 38418 21 CCyR Y 21 H396R 70%, M244V 10% 2 H396R M244V 2 NA 10 KSB 30/3/05 e355g:63.9,f359v:26.44,g321g:2.48,s438f:1.65,e431k:1.62,n358s:1.01 KSB M 58.3260273972603 resistant AP dasatinib 38441 35 MCyR Y 3 E355G 75%, F359V 25% 2 F359V E355G M244V 3 T315I, M244V 3 11 YRC 21/4/05 m244v:35.75,e255v:19.27,e355a:18.26,g249d:12.48,e459k:6.4,l248v:4.6,m351t:3.86,s438f:2.36,g321g:2.17,g250e:1.7,i443i:1.67,f486s:1.4,e453g:1.25,g249a:1.24,w478l:1.08,v379i:1.02,t277a:0.9,t495a:0.76,e292g:0.64,k291k:0.55 YRC M 52.5369863013699 resistant AP dasatinib 38463 24 no MCyR NA M244V 50%, E255V 10%, M351T 10% 3 E255V M351T F486S M244V E279K L248V E459K 1064A>C (E355A) 8 L248V/ E355A/T315I 24 12 LAB 21/4/05 a397p:37.16,y253h:25.58,f317l:5.3,f401f:2.18,g321g:2.04,m351t:1.74,s438f:1.58,e431k:1.35,p230p:1.17,p408t:0.94,f382l:0.81,n479s:0.81,k294r:0.73,k285e:0.59,v256a:0.43,e286e:0.4,l284s:0.39,k274e:0.39,k247e:0.33,k274r:0.31 LAB M 63.5424657534247 resistant AP dasatinib 38463 30 MMR Y 3 Y253H 50%, A397P 60% 2 M351T F317L(949T>C) Y253H 3 F317L 22 13 SAK 16/5/05 f359v:81.52,t315i:12.05,g321g:1.54,m351v:1.4,y312y:1.4,r483q:1.34,s349s:1.06,e292g:0.89,m351t:0.73,a288a:0.65,d276g:0.65,k291k:0.43 SAK M 35.4958904109589 resistant AP dasatinib 38488 3 no MCyR NA T315I 25%, F359V 70% 2 F359V T315I 2 NA 14 GLL 30/5/05 h396r:34.88,a397p:10.2,f359i:4.23,f359v:4.1,y253f:3.79,g321g:2.4,f401f:1.98,s438f:1.76,d363y:0.84,e459a:0.69 GLL F 47.4328767123288 resistant AP dasatinib 38502 18 no MCyR NA H396R 30%, A397P 15% 2 H396R F359I F359V Y253F 4 T315I 15 15 MAP 6/6/05 t315i:55.62,g250e:11.76,m351t:8.7,s417y:7.43,h396r:5.89,m244v:3.37,g321g:2.51,p230p:2.46,f359v:2.3,y253f:2.15,s438f:1.57,w430l:1.27,e459k:1.09,t495a:0.91,d276g:0.77,f486s:0.74 MAP M 59.6219178082192 resistant AP dasatinib 38509 1 no MCyR NA T315I 60%, G250E 10%, M351T 5%, H396R 5%, S417Y <5% 4 M351T H396R F359V Y253F M244V F359C G250E L248V T315I 9 NA 16 JHC 16/6/05 e453k:26.77,h396r:11.87,m244v:5.14,m351t:4.46,g321g:2.24,i313t:0.77,k291k:0.6 JHC M 47.4465753424658 resistant AP dasatinib 38519 33 no MCyR NA H396R 15%, E453K 50% 2 M351T H396R M244V 3 NA 17 SP 23/6/05 t315i:35.31,e459k:9.82,h396r:5.31,f317l:3.23,g321g:2.51,e459g:1.75,m351t:1.71,k262t:0.66,v228a:0.45,k263e:0.42,k262r:0.39,k263k:0.37,v268a:0.37,k274e:0.33 SP M 22.1835616438356 resistant AP dasatinib 38526 7 no MCyR NA T315I 45% 3 M351T H396R F317L(951C>A) L248V T315I E459K 6 NA 18 DAJ 29/8/05 y253f:63.44,f359i:33.11,g321g:2.24,p230p:2.18,e308*:1.46 DAJ 51 resistant BC nilotinib 38593 3 no MCyR NA Y253F 65%, F359I 35% 2 F359I Y253F 2 NA 19 LCM 5/4/06 t315i:27.92,g250e:14.75,m343i:11.76,p230p:2.75,e236*:2.2,f401f:2,a412s:1.84,g321g:1.6,f317l:1.13,e308*:1.09,a399s:1.04,n331k:0.96 LCM 36 resistant BC nilotinib 38812 1 no MCyR NA G250E 15%, T315I 40% 2 F317L(951C>A) G250E T315I 3 NA 20 PMP 28/3/05 m472i:91.13,f359v:8.47,g321g:2.13,f401f:1.71,s438f:1.66,e255k:1.43,e431k:1.38,p408t:1.05,p441r:1.03,v304f:0.94,h396r:0.87,i489v:0.59,k262r:0.58 PMP NA resistant BC dasatinib 38439 8 no MCyR NA 1416G>A 90%, F359V <5% 2 H396R F359V 2 F317L 100% 6 21 CSC 26/4/05 h396r:81.51,t315i:13.57,p465s:3.34,a412a:2.4,g321g:1.85,s438f:1.76,v448v:0.98 CSC NA resistant BC dasatinib 38468 2 no MCyR NA H396R 90%, T315I 25% 2 H396R T315I 2 NA 22 VAP 18/5/05 g250e:38.92,m244v:21.73,y253f:15.88,e255v:5.15,f317l:3.86,f359c:2.37,y253h:1.28,l387m:1.25,k291k:0.62,e459k:0.56,k263e:0.54,d276g:0.51,n336s:0.48,m351t:0.48,i432v:0.48,k285k:0.47,e238e:0.46,k294r:0.46,k247r:0.4,k400r:0.4,t495a:0.4,k262r:0.4,n368s:0.39,e279k:0.39,h361r:0.38,e281e:0.35,e286e:0.35,k467r:0.31,f359l:0.31 VAP NA resistant Ph+ ALL/LBC dasatinib 38490 4 no MCyR NA M244V 30%, G250E 35%, Y253F 35% 3 E255V Y253F M244V F359C F317L(951C>A) G250E L248V E459K 8 V299L, F317L(951C>A) 4 23 NA NA NA LCG NA resistant Ph+ ALL/LBC dasatinib 38516 4 no MCyR NA Y253H 55%, M351T <10% 2 M351T H396R F486S F359V Y253H M244V G250E L248V E459K 9 F317L 4 24 IC 7/26/2010 e255k:37.52,e255v:11.65,f401f:2.67,q252h:2.64 IC F 57.3 newly diagnosed CP none- imatinib first line 40385 12 failure- mut at 3 months Y 3 NA NA Q252H 30%, E255K 10%, E255V 3 25 MT 5/26/2009 q252h:36.94,e255k:25.13,t315i:17.57,y253h:11.73,e255v:4.45,f359v:3.09,g249d:0.83,g321g:0.64,t495a:0.42 MT M 37 newly diagnosed CP none- imatinib first line 39959 4 Progression to BC at 4 mo N NA NA NA Q252H 30%,Y253H 15%,E255K 20%,T315I 30% 3 26 PMR 27/7/05 m244v:66.3,g250e:1.06,y449h:0.95,m290v:0.69,n374d:0.68,c305f:0.6,t495a:0.57,q300*:0.53,e238g:0.52,i242v:0.48,s410g:0.47,k262r:0.44,n336s:0.38,e238e:0.31,l452p:0.3,k454r:0.28,w476*:0.26,e292g:0.24,f283s:0.22 PMR 55 resistant CP nilotinib 38560 21 progression NA M244V 60% 1 M244V 1 G250E/T315I 18 27 LE 12/10/05 f359v:99.78,n479s:0.57,n414s:0.56,n374s:0.46,k291k:0.43,i293v:0.42,t495a:0.42,k294r:0.41,k378r:0.4,n336s:0.37,e236g:0.36,n374d:0.35,f283s:0.34,h361r:0.34,k245r:0.31,k262r:0.31,k454e:0.31,y456c:0.29 LE M 65 resistant CP nilotinib 38637 8 progression NA F359V 100% 1 F359V 1 NA 28 DLP 19/10/05 e279k:93.77,l387m:6.16,g463d:0.92,t277a:0.67,n358s:0.57 DLP F 69 resistant CP nilotinib 38644 21 CCyR Y 6 E279K 100% 1 E279K 1 NA 29 CRE 1/5/06 t315i:97.89,a412s:4.24,p441l:1.68,a395t:0.98,e255k:0.97,n368s:0.89,c330r:0.86,d233y:0.85,t315v:0.73,f425l:0.66,g303g:0.65,n358s:0.65,f317l:0.56,k415k:0.52,q333q:0.51,t345a:0.51,e286g:0.5,a399s:0.5,k262n:0.49,f283s:0.48,h246r:0.48,p465p:0.47,t495a:0.46,k263k:0.45,m458r:0.44,v289a:0.42,l445l:0.4,k294e:0.38,k294k:0.37,d444g:0.37,k262k:0.36,g398e:0.36,e281e:0.34,k262r:0.33,f317s:0.3,n336s:0.3,l354l:0.3,e462k:0.29,i432v:0.28,n479d:0.27,k291k:0.26,e292g:0.26,t243a:0.24,q300r:0.23 CRE 65 resistant CP nilotinib 38838 3 progression NA T315I 100% 1 T315I F317L (951 C>A) 2 NA 30 NA NA NA DFF 69 resistant CP nilotinib 38784 18 failure - no cyto resp 6m NA M351T 90% 1 M351T F486S F317L (951C>A) 3 F317L 4 31 GR 7/4/06 m351t:64.59,h396r:11.67,g250e:4.5,f359i:2.6,s438c:1.52,e355g:1.03,a412s:0.98,f317l:0.73,h396d:0.72,a399s:0.69,t495a:0.65,n336s:0.5,k245r:0.46,e238e:0.45,k454r:0.44,k294e:0.43,v228a:0.43,k294r:0.43,e470e:0.42,k247e:0.4,n336d:0.4,k291k:0.4,k263e:0.39,q252r:0.38,t389a:0.38,k271r:0.37,f497l:0.36,g227g:0.34,y393h:0.32,v289a:0.3,d444g:0.29 GR 45 resistant CP nilotinib 38814 3 failure - no cyto resp 3m NA M351T 70% 1 M351T H396R F359I E355G G250E 5 G250E, F359I BM only/H396R 3 32 REL 1/9/05 y253h:99.4,k285k:0.62,t495a:0.62,k291e:0.57,e292g:0.5,k294r:0.5,e238e:0.49,n336d:0.47,k271r:0.46,n358s:0.45,e352g:0.42,e470g:0.42,k291k:0.42,n374d:0.4,n358d:0.37,k274e:0.37,e281e:0.37,k454r:0.36,r473r:0.36,k467e:0.35,t306a:0.35,l273l:0.34,k294e:0.34,t434a:0.34,m318v:0.32,k294k:0.31,k247e:0.3 REL 60 resistant CP nilotinib 38596 6 progression NA Y253H 100% 1 Y253H 1 NA 33 NA NA NA MF F 69.6493150684932 resistant CP dasatinib 38439 2 Minimal cyto response at 3m NA M351T 80% 1 M351T 1 NA 34 KA 9/4/05 g250e:98.6 KA F 45.9068493150685 resistant CP dasatinib 38451 32 CCyR Y 3 G250E 100% 1 G250E 1 NA 35 VL 5/5/05 e255v:98.97,w423*:0.76,t495a:0.72 VL M 64.8876712328767 resistant CP dasatinib 38477 24 failure - no cyto resp 3m NA E255V 100% 1 E255V 1 T315I 15 36 DHD 16/5/05 e459k:98.82,g250e:0.77,k291k:0.53 DHD F 65.2657534246575 resistant CP dasatinib 38488 17 achieved MCyR NA E459K 100% 1 E355G E459K G250E 3 F317L ?G250E 6 37 SF 31/5/05 a397p:98.99 SF F 44.586301369863 resistant CP dasatinib 38503 33 CCyR Y 3 A397P 100% 1 none 0 NA 38 IW 7/6/05 w430r:8.36,e279k:6.88,k247*:2.45,k419r:1.26,l445p:1.08,g251g:0.7,s481p:0.62,k263k:0.6,t495a:0.56,q491r:0.43,g249d:0.42,e462e:0.36,k454r:0.33,w476r:0.29,k263e:0.28,k247e:0.28,e470g:0.28,i489v:0.27,e494e:0.27,y226c:0.26,f486s:0.26 IW F 42.1178082191781 resistant CP dasatinib 38510 33 CCyR Y 3 E279K 25% 1 E279K 1 NA 39 BHK 24/5/05 t315i:79.57,e236*:11.85,g372w:11.02,l387f:9.43,v377l:9.26,d363y:8.96,f283s:8.91,r386s:6.42,q346*:3.2,k454r:2.3,n374s:2.21,p461p:2.04,e282g:1.97,k245r:1.93,h490h:1.79,i432v:1.39,y312y:1.37,d391g:1.06,y435h:0.81 BHK M 31.641095890411 resistant AP dasatinib 38496 6 no MCyR NA T315I 90% 1 T315I 1 NA 40 JGK 24/5/05 m351t:99.54,v379a:2.36,e409g:0.6,t495a:0.57,v228a:0.53,d444g:0.48,r473r:0.37 JGK M 45.4493150684931 resistant AP dasatinib 38496 32 MMR Y 2 M351T 90% 1 M351T 1 NA 41 CWS 15/6/05 m351v:84.86,g303g:0.65,t495a:0.62,k234e:0.56,r483w:0.5,e281e:0.47,e238e:0.42,k245r:0.38,c305r:0.34,n414s:0.34,k271r:0.33,k291k:0.33,t277a:0.31,e292g:0.31,k271e:0.29,e450g:0.26,k454r:0.25,y449h:0.21,k454e:0.18 CWS M 24.2301369863014 resistant AP dasatinib 38518 33 lost MCyR Y 3 M351V (1051A>G) 90% 1 none 0 NA 42 RWB 7/11/05 m244v:96.76,q252h:2.17,r362g:0.64 RWB 64 resistant BC nilotinib 38663 2 no MCyR NA M244V 100% 1 M244V Q252H(G>C) 2 F359V Y253H E255K 1 43 RW 15/12/06 v299l:70.98,n374d:0.74,k294e:0.69,f359l:0.65 RW 29 resistant BC nilotinib 39066 3 no MCyR NA V299L (G>T) 70% 1 V299L(G>T) 1 NA 44 LY 20/6/06 l248v:97.01,k285e:0.69,t495a:0.62,e494e:0.6,v228a:0.56,e292g:0.54,f382l:0.52,f283s:0.49,m472v:0.46,k291k:0.4,f486s:0.31 LY 57 resistant BC nilotinib 38888 2 no MCyR NA L248V 100%, del ~20% 1 L248V 1 NA 45 DMJ 12/7/06 f317i:95.58,w476c:10.02,f401s:3.26,a412s:2.41,e308*:2.09,k262n:1.81,e236*:1.69,f317l:1.68,v299l:1.61,w261c:1.44,t240a:0.9,r386s:0.87,l340l:0.78,v339l:0.77,p441p:0.6 DMJ 53 resistant BC nilotinib 38910 2 no MCyR NA F317I 100% 1 F317I V299L(G>T) 2 E255V 2 46 DKK 23/3/05 t315i:77.07,q252h:10.24,g463g:6.91,r307w:5.09,e355g:3.05,e238e:2.4,t389a:1.18,f416l:1.18 DKK NA resistant BC dasatinib 38434 1 no MCyR NA T315I 80% 1 Q252H(G>C) T315I 2 NA 47 MA 9/11/05 k378e:15.95,f317l:4.52,s385g:3.43,y226y:2.03,k285n:1.81,a433v:1.75,r332w:1.48,t345a:1.09,y253h:1.03,m278v:0.97,p309p:0.78,p461l:0.46,c330r:0.44,v228a:0.43,q300r:0.41,l324l:0.4,y456h:0.36,n336s:0.35,k467r:0.33,m351v:0.32,y257c:0.31,d444g:0.3,s229p:0.3,c305r:0.29,y469y:0.28,t495a:0.28,g227g:0.27,k247r:0.25,e238g:0.25,d455g:0.25,r239h:0.24,t243a:0.23,n336d:0.23,k291k:0.23,h490r:0.2,k247e:0.18,t315i:0.01 MA 70 resistant Ph+ ALL/LBC nilotinib 38665 3 no MCyR NA F317L (949T>C) 15% 1 F317L(949T>C) Y253H 2 Y253H 3 48 EAM 29/4/05 l248v:95.59,e409d:1.03,s481p:0.83,n479d:0.78,m237i:0.69,k378r:0.69,v339m:0.64,l387s:0.61,t495t:0.6,v228a:0.59,n374d:0.56,r239c:0.55,k245e:0.53,n414s:0.53,d233g:0.51,y469y:0.5,n336s:0.5,g227g:0.48,t240a:0.48,n336d:0.48,q447r:0.48,t495a:0.47,n358d:0.47,e352g:0.46,k291k:0.46,e238e:0.44,c305r:0.44,d363d:0.44,k294k:0.42,k285r:0.42,l301p:0.41,n331s:0.41,n374s:0.41,p439p:0.41,t392a:0.4,t389a:0.39,k234r:0.38,k356e:0.37,e281e:0.36,n358s:0.34,l340p:0.33,l302l:0.33,l284s:0.32,r473r:0.32,l354p:0.31,d444g:0.29 EAM NA resistant Ph+ ALL/LBC dasatinib 38471 27 CCyR Y 4 L248V 100%, del ~25% 1 L248V 1 NA 49 LAZ 6/3/06 d276g:51.65,t315i:5.03,e275d:3.99,w261c:3,e275*:2.84,e236q:1.82,g398v:1.42,y440h:1.29,p310s:1.2,k274n:1.06,s349p:1.05,t243i:1.03,t240t:1.02,g303g:0.96,e308*:0.9,a399s:0.9,h246q:0.88,r328m:0.86,s446s:0.85,d363y:0.81,e281*:0.78,e255*:0.74,g321r:0.74,a344g:0.72,e466d:0.72,k400e:0.7,y440y:0.66,t495a:0.66,s446p:0.61,e292*:0.6,k404k:0.59,l411l:0.56,n336d:0.54,h375h:0.54,n358s:0.53,k291k:0.53,k467r:0.52 LAZ F 45 resistant CP nilotinib 38782 3 progression NA D276G 50% 1 D276G T315I 2 T315I 1 50 SOP 31/10/06 g250e:40.92,m351t:21.88,t315i:5.67,e255v:1.75,k262n:1.6,a412s:1.19,e236*:0.9,t495a:0.9,r386s:0.82,w261c:0.71,g227g:0.68,n368s:0.67,e292g:0.65,w478c:0.62,n336d:0.6,f486l:0.57,k294e:0.56,k262r:0.51,r483w:0.51,e286e:0.46,f317l:0.44,t495t:0.42,v448a:0.41,h490r:0.4,m496v:0.31 SOP 69 resistant CP nilotinib 39021 10 progression NA G250E 30%, M351T 25% 2 E255V M351T G250E T315I F359V 5 E255V, T315I/F359V 1 51 DJS 1/4/05 g250e:81.05,t495a:0.5,l341p:0.46 DJS F 32.6520547945205 resistant CP dasatinib 38443 9 progression Y 3 G250E 75% 1 G250E 1 T315I 4 52 CPH 24/5/05 m244v:43.37,e459g:10.02,y253h:9.18,f359v:8.74,e355g:8.32,e255k:3.99,i293v:0.63,e450g:0.48 CPH M 56.0849315068493 resistant CP dasatinib 38496 11 MCyR Y 12 M244V 50%, Y253H 10% 1 F359V Y253H E355G M244V T315I E255K 6 Y253H, T315I, E255K 2 53 MHB 7/6/05 g249d:1.03,l341l:1.01,n231s:0.8,n336s:0.59,k263k:0.55,t495a:0.49,l429p:0.47,m496v:0.34,f283s:0.32,k294k:0.3,k274r:0.3,e238e:0.28,k294r:0.28,k294e:0.27 MHB M 43 resistant CP dasatinib 38510 10 Minimal cyto response NA no mutation 0 T315I 1 T315I 6 54 VMM 6/7/05 e355g:82.8,t315i:4.47,e453k:3.72,f359v:1.18,e450g:0.76,t495a:0.63,k357k:0.54,n358s:0.44,k467r:0.4 VMM F 65.7150684931507 resistant CP dasatinib 38539 17 failure - no responseno cyto response 3m NA E355G 80% 1 F359V E355G T315I 3 T315I, F317L 2 55 MJK 20/7/05 e286g:0.58,e494e:0.56,e292g:0.55,f486s:0.52,n374s:0.52,e281e:0.51,i432v:0.5,e488e:0.49,k467e:0.49,n358s:0.44,k262r:0.43,t389a:0.43,k234r:0.42,t306a:0.42 MJK 33.4383561643836 resistant CP dasatinib 38553 4 progression NA no mutation 0 T315I 1 T315I 2 56 AD 31/3/05 a397p:97.12,e453d:6.13,t315i:1.88,k262n:1.1,t277a:1.05,w261c:0.93,t319a:0.72,t495a:0.64,r457s:0.62,r386s:0.61,r332l:0.53,k291k:0.51,e292g:0.44,a407v:0.44,t240a:0.43,e281e:0.43 AD F 63.5095890410959 resistant AP dasatinib 38442 18 no MCyR NA A397P 100% 1 T315I 1 T315I 3 57 AFN 2/5/05 f359v:46.9,e255k:27.75,f486s:16.8,m244v:3.42,t315i:2.84,m351t:1.87,e255v:1.56,n358s:0.88,p309l:0.7,t495a:0.58,a399v:0.57,k262r:0.54,v335a:0.54,p310s:0.52,n336s:0.52,y253h:0.52,l284s:0.39 AFN M 62.5808219178082 resistant AP dasatinib 38474 9 no MCyR NA E255K 25%, F359V 35% 2 E255V M351T F486S F359V M244V T315I E255K 7 M244V 9 58 JYN 20/6/05 s417y:77.82,l387m:5.92,t315i:1.58,f317l:1.35,e355g:0.75,e355a:0.6,k357k:0.59,t495a:0.57,i432v:0.53,k234e:0.52,k291e:0.51,k291k:0.5,k294k:0.49,f382l:0.49,d363d:0.48,k285k:0.46,k357e:0.46,k262r:0.45,k294r:0.44,k274r:0.44,n374s:0.44,i489v:0.42,m244v:0.42,n358s:0.42,n374d:0.4,e238e:0.4,e292g:0.4,k454r:0.39,n368s:0.38,v260a:0.38,k263k:0.37,e334g:0.37,l364p:0.37,k357r:0.36,k263e:0.36,v228a:0.34,d325g:0.33,l284s:0.33,t389a:0.32,t277a:0.31,f283s:0.29,k245r:0.27 JYN F 65.2465753424657 resistant AP dasatinib 38523 9 no MCyR NA S417Y 70% 1 E355G F317L(951C>G) T315I 3 T315I 9 59 ARS 2/11/05 t495a:0.73,n336s:0.49,k291k:0.46,d276g:0.41,k294e:0.39,n358s:0.39,e238e:0.37,n368s:0.36,m318v:0.3,t434a:0.3 ARS 66 intolerant BC nilotinib 38658 1 no MCyR NA no mutation 0 T315I 1 T315I 1 60 ABS 12/5/05 l248v:35.25,f486s:18.11,m351t:8.1,e459k:6.15,f359v:4.5,h396r:4.24,l273m:4.05,g250e:2.33,f359c:2.02,e355g:1.91,k285k:0.61,m244v:0.58,k291k:0.57,k247r:0.56,t495a:0.52,k294r:0.5,k294k:0.48,f283l:0.46,e238e:0.44,f317l:0.44,k247e:0.44,k262r:0.44,e431e:0.44,k454e:0.43,k263k:0.42,e470g:0.42,n479s:0.42,i432v:0.41,i489v:0.41,e494g:0.41,e286g:0.4,l387l:0.4,e431g:0.39,n414s:0.38,k378r:0.37,i314t:0.37,k245r:0.36,e281e:0.36,e352g:0.36,f382l:0.36,n336s:0.35,t267a:0.35,e292g:0.34,m496v:0.34,d391g:0.33,k274r:0.32,e286e:0.32,a407a:0.32,k419e:0.32,d325g:0.32,k415r:0.32,h490r:0.32,f311s:0.31,e470e:0.3,k467r:0.29,f283s:0.29,m437v:0.29,q300r:0.28,r386g:0.27,t394t:0.27,n231d:0.26 ABS NA resistant BC dasatinib 38484 12 no MCyR NA L248V 60%, F486S <10% 2 M351T H396R F486S F359V E355G F359C G250E L248V T315I E459K 10 T315I 12 61 JHL 11/5/05 t315i:1.9,f493l:0.5,g249d:0.32,t267a:0.23 JHL NA resistant BC dasatinib 38483 1 no MCyR NA no mutation 0 T315I 1 T315I 1 62 AHP 10/10/06 f317l:97.5,c305r:4.06,a412s:2.61,p230p:2.31,v299l:2.22,g321g:1.38,e431k:1.38,g398g:1.3,v304f:1.26,t240t:1.21,d325n:1.11,g227c:1.01,e292k:0.63,k467r:0.62 AHP 75 resistant CP nilotinib 39000 6 failure - no cyto resp 3m NA F317L (951C>G) 100% 1 V299L(G>C) F317L(951C>G) 2 Q252H 4 63 AHP 5/12/06 f317l:98.44,g249s:2.75,p230p:2.44,g321w:2.08,f401f:2.02,a412s:2.02,m237i:1.8,v299l:1.72,e236*:1.47,e308k:1.41,g321g:1.33,e258*:1.25,e431k:1.24,a397s:1.11,f311l:1.1,r386s:1.03,e279d:1.02,a337s:0.94,n331k:0.92,e373d:0.87,a399s:0.76,d455e:0.64 AHP 75 resistant CP nilotinib 39000 6 failure - no cyto resp 3m NA F317L (951C>G) 100% 1 V299L(G>C) F317L(951C>G) 2 Q252H 4 64 AHP 6/3/07 f317l:87.37,q252h:11.27,e450d:2.92,v260v:2.7,y320y:2.3,p230p:2.13,k262m:2.12,v256v:2.08,f401f:1.94,d363y:1.78,d241d:1.78,g321g:1.71,p441r:1.01,s417p:0.73,r473r:0.59 AHP 75 resistant CP nilotinib 39000 6 failure - no cyto resp 3m NA F317L (951C>G) 100% 1 V299L(G>C) F317L(951C>G) 2 Q252H 4 65 MZ 24/5/06 e355g:8.64,n368n:4.01,e279*:3.89,k245r:3.73,p230p:2.85,g321g:2.2,q333h:2.16,c475f:2.02,q491q:0.87 MZ 44 resistant CP nilotinib 38861 6 failure - no cyto resp 6m NA E355G 1 E355G 1 T315I 6 66 MZ 26/7/06 e355g:60.4,p230p:1.77,t306i:1.39,g321g:1.32,y264c:1.22,a397t:1.12,w478*:0.67 MZ 44 resistant CP nilotinib 38861 6 failure - no cyto resp 6m NA E355G 1 E355G 1 T315I 6 67 MZ 11/10/06 t315i:13.89,e355g:7.45,g321g:2.14,p230p:1.93,s438f:1.57,f401f:1.52,a395g:1.11,e373k:1.05,e431k:0.99,p441r:0.95,r307p:0.85,k291k:0.8,k357e:0.75,t495a:0.61,q491q:0.59,f311s:0.51 MZ 44 resistant CP nilotinib 38861 6 failure - no cyto resp 6m NA E355G 1 E355G 1 T315I 6 68 HL 1/6/05 q252h:62.06,e255k:18.25,h396r:15.81,r362i:7.68,g463s:6.82,s348s:5.1,i242t:5.05,h490r:2.32,g321g:2.01,t392t:2.01,a395v:1.87,f401f:1.57,h396d:1.23,r460r:1.18,a288v:1.16,e494e:1.14,e281g:0.92 HL M 82.2164383561644 resistant CP dasatinib 38504 5 failure- mut at 3 months NA Q252H (G>T) 80%, E255K 15%, H396R 30% 3 H396R Q252H(G>T) E255K 3 T315I 4 69 HL 1/7/05 e255k:83.58,q252h:11.57,h396r:6.54,s438f:1.52,g321g:1.5,a395a:1.27,e431k:1.1,f497f:1.01,v299v:0.96,d363g:0.89,g227g:0.64 HL M 82.2164383561644 resistant CP dasatinib 38504 5 failure- mut at 3 months NA Q252H (G>T) 80%, E255K 15%, H396R 30% 3 H396R Q252H(G>T) E255K 3 T315I 4 70 HL 1/8/05 e255k:91.65,t315i:5.16,i242t:2.72,g321g:1.87,p230p:1.75,s438f:1.54,q252h:1.26,e431k:1.18,l376l:0.9,f283s:0.58,t495a:0.53,e236g:0.52,d444g:0.42 HL M 82.2164383561644 resistant CP dasatinib 38504 5 failure- mut at 3 months NA Q252H (G>T) 80%, E255K 15%, H396R 30% 3 H396R Q252H(G>T) E255K 3 T315I 4 71 HL 21/10/05 t315i:67.17,e255k:39.66,p230p:2.05,f401f:1.43,g321g:1.31,g303w:1.2,f425l:0.86,g249d:0.74,k291k:0.74,e352g:0.68 HL M 82.2164383561644 resistant CP dasatinib 38504 5 failure- mut at 3 months NA Q252H (G>T) 80%, E255K 15%, H396R 30% 3 H396R Q252H(G>T) E255K 3 T315I 4 72 MDL 15/6/05 l248v:80.16,f359i:6.03,g321g:1.89,m244v:1.73,e450k:1.32,l387m:0.95,e238e:0.74,m318v:0.54 MDL M 46.3205479452055 resistant CP dasatinib 38518 20 progression NA L248V 100% 1 F359I M244V L248V 3 V299L 6 73 MDL 02/12/05 l248v:34.47,v299l:29.48,g321g:1.29,s438f:1.24,a399s:1.08,a399a:0.98,v304f:0.85 MDL M 46.3205479452055 resistant CP dasatinib 38518 20 progression NA L248V 100% 1 F359I M244V L248V 3 V299L 6 74 MDL 28/2/07 l248v:20.38,s438p:5,y353c:1.34,w261c:0.8,r239r:0.78,e281e:0.73,l248r:0.72,p480p:0.72,y257h:0.59,l411l:0.49,t495a:0.46,f486f:0.46,n358s:0.44,n336d:0.4,v289a:0.38,f497f:0.38,k263k:0.37,k291k:0.34,v299l:0.29,t277a:0.28,v448l:0.28,n336s:0.26 MDL M 46.3205479452055 resistant CP dasatinib 38518 20 progression NA L248V 100% 1 F359I M244V L248V 3 V299L 6 75 CO 5/7/05 g250e:96.43 CO F 54.2712328767123 resistant CP dasatinib 38538 30 failure - no responseno cyto response 9m NA G250E 100% 1 G250E 1 F317L 24 76 CO 5/12/07 f317l:97.02,g250e:96.39,p439l:2.77,e499e:1.93,d421d:1.55 CO F 54.2712328767123 resistant CP dasatinib 38538 30 failure - no responseno cyto response 9m NA G250E 100% 1 G250E 1 F317L 24 77 LK 24/3/06 e255k:96.96,e236d:9.62,y253h:3.55,a412s:1.77 LK 75 resistant AP nilotinib 38800 9 no MCyR NA E255K 100% 1 Y253H E255K 2 Y253H 1 78 NA NA NA LK 75 resistant AP nilotinib 38800 9 no MCyR NA E255K 100% 1 Y253H E255K 2 Y253H 1 80 CSY 21/3/05 f359c:95.41,p230p:3.66,g321g:2.89,f401f:2.56,s438f:2.28,w430l:1.68,e373k:1.54,e308k:1.27,e431k:1.16,t306n:0.92,p408t:0.91,k294e:0.75,k245r:0.52 CSY M 64.0739726027397 resistant AP dasatinib 38432 34 no MCyR NA F359C 100% 1 F359C 1 T315I 15 81 CSY 28/3/06 f359c:99.56,t315i:7.2,r460r:3.74,g259c:3.07,p230p:3.06,s229f:2.99,e281*:2.84,g321g:2.57,r328s:2.23,f401f:2.2,k271t:2.08,e308*:2.03,e462a:1.84,w405c:1.83,g321w:1.82,f382c:1.76,n322k:1.76,e431k:1.74,g398v:1.7,p408t:1.7,v338m:1.68,s438f:1.62,p441l:1.53,r386s:1.52,e409d:1.46,k271e:1.4,n414s:1.21,k262n:1.12,v304f:1.08,e373k:1.04,m458i:1.02,n331k:1,v371l:0.95,w261c:0.94,t306n:0.94,a487t:0.92,d444y:0.91,a337v:0.86,s446f:0.85,s446s:0.85,s348s:0.78,d241g:0.74,e308v:0.74,e466*:0.7,e470g:0.66,r386m:0.58,k262r:0.56,v335a:0.48 CSY M 64.0739726027397 resistant AP dasatinib 38432 34 no MCyR NA F359C 100% 1 F359C 1 T315I 15 82 CSY 22/1/08 f359c:99.74,t315i:99.65,a350a:20.38,e352d:17.87,p230p:3.38,g321g:2.94,f401f:2.4,s438f:1.8,e255k:1.69,s229f:1.65,e431k:1.43,w430l:1.3,p408t:1.04,s485p:0.8 CSY M 64.0739726027397 resistant AP dasatinib 38432 34 no MCyR NA F359C 100% 1 F359C 1 T315I 15 83 JLR 29/4/05 f317l:90.63,y253h:7.76,p230p:2.52,t306n:1.52,e431k:1.32,k291k:1.11 JLR M 45.6876712328767 resistant AP dasatinib 38471 18 no MCyR NA Y253H 10%, F317L (951C>A) 90% 2 Y253H F317L(951C>A) 2 T315I 18 84 JLR 12/11/07 f317l:51.59,y253h:44.59,t315i:38.49,f401f:3.08,p230p:2.86,d276e:2.85,g321g:2.3,s438f:1.38,g251a:1.29,e255k:1.28,s229f:1.28,e431k:1.05,w430l:1.04,e308k:0.93,v304f:0.78,s446f:0.61,t306n:0.54,r457c:0.43,k245r:0.34,e470g:0.3 JLR M 45.6876712328767 resistant AP dasatinib 38471 18 no MCyR NA Y253H 10%, F317L (951C>A) 90% 2 Y253H F317L(951C>A) 2 T315I 18 85 RE 4/5/05 g250e:96.16,p230p:3.09,f401f:2.49,g321g:2.36,s438f:2.11,h396r:2.08,g303w:1.56,e308k:1.5,e431k:1.27,w430l:1.22,n331k:0.96,p408t:0.91,v268v:0.65 RE F 61.3643835616438 resistant AP dasatinib 38476 16 no MCyR NA G250E 100% 1 H396R G250E 2 T315A 16 86 NA NA NA RE F 61.3643835616438 resistant AP dasatinib 38476 16 no MCyR NA G250E 100% 1 H396R G250E 2 T315A 16 87 NEF 16/5/05 f359c:98.96,p230p:2.45,g321g:1.54,n331k:1.35 NEF F 48.9013698630137 resistant AP dasatinib 38488 16 no MCyR NA F359C 100% 1 F359C 1 V299L 16 88 NEF 25/9/06 f359c:99.1,v299l:77.82,f317l:7.72,y440y:2.59,p230p:2.19,g321g:1.92,f317i:1.58,g251a:1.28,s438f:1.1,w430l:0.78,v304f:0.76,e308k:0.66,r328k:0.5 NEF F 48.9013698630137 resistant AP dasatinib 38488 16 no MCyR NA F359C 100% 1 F359C 1 V299L 16 89 LYS 27/5/05 t240a:86.15,y253f:77.14,h396r:18.01,i347i:3.7,g321g:2.73,g250e:2.48,a407a:2.26 LYS M 63.7342465753425 resistant AP dasatinib 38499 5 no MCyR NA Y253F 90%, H396R 20%, T240A 80% 3 M351T H396R Y253F G250E 4 T240A 40%, G250E 60%, 5 90 NA NA NA LYS M 63.7342465753425 resistant AP dasatinib 38499 5 no MCyR NA Y253F 90%, H396R 20%, T240A 80% 3 M351T H396R Y253F G250E 4 T240A 40%, G250E 60%, 5 91 DVD 29/6/05 e279k:87.53,g321g:2.63 DVD F 60.3178082191781 resistant AP dasatinib 38532 18 no MCyR NA E279K 90% 1 E279K 1 T315I F317L 12 17 Nov 2006 Sample - Lost of MCyR 92 DVD 17/11/06 t315i:74.74,e279k:31.16,f317l:22.11,m458i:5.48,k285e:4.61,p230p:2.59,g259v:2.15,g321g:2.06,r386s:1.66,e236*:1.57,k262n:1.2,g249d:0.98,w430l:0.82 DVD F 60.3178082191781 resistant AP dasatinib 38532 18 no MCyR NA E279K 90% 1 E279K 1 T315I F317L 12 17 Nov 2006 Sample - Lost of MCyR 93 DVD 11/1/07 t315i:78.68,e279k:22.35,f317l:15.77,w478l:4.13,d482d:2.76,n331s:2.27,p230p:2.19,k262n:2.08,g321g:1.59,v304f:0.94 DVD F 60.3178082191781 resistant AP dasatinib 38532 18 no MCyR NA E279K 90% 1 E279K 1 T315I F317L 12 17 Nov 2006 Sample - Lost of MCyR 94 BRM 21/12/05 m244v:79.49,d276g:5.31,g321g:1.88 BRM 46 resistant BC nilotinib 38707 5 no MCyR NA M244V 70% 1 D276G M244V 2 D276G/E255V 3 95 BRM 8/5/06 m244v:99.67,e255v:94.58,f401f:1.88,p230p:1.82,e255k:1.6,g321g:1.33,e255l:0.84,e308*:0.8,g426g:0.52 BRM 46 resistant BC nilotinib 38707 5 no MCyR NA M244V 70% 1 D276G M244V 2 D276G/E255V 3 96 EEC 25/4/05 h396r:65.56,g250e:19.96,f486s:13.14,e279k:5.95,h396d:2.53,s438f:1.94,f401f:1.55,h396s:1.17,p408t:0.92 EEC NA resistant BC dasatinib 38467 8 no MCyR NA H396R 65%, G250E 15%, F486S 10% 3 H396R F486S G250E E279K 4 F317L x2 8 97 EEC 27/12/05 g250e:43.38,f317l:38.98,g321g:2.07 EEC NA resistant BC dasatinib 38467 8 no MCyR NA H396R 65%, G250E 15%, F486S 10% 3 H396R F486S G250E E279K 4 F317L x2 8 98 DWB 14/6/05 m351t:99.88,p230p:2.64,g321g:2.29,f401f:1.61 DWB NA resistant BC dasatinib 38517 3 no MCyR NA M351T 100% 1 M351T 1 T315I 3 99 DWB 21/9/05 m351t:98.3,t315i:44.8,g321g:1.93 DWB NA resistant BC dasatinib 38517 3 no MCyR NA M351T 100% 1 M351T 1 T315I 3 100 MT 2/17/2009 p230p:2.1,f401f:2.08,g321g:1.82,s438f:1.22,g249d:1.17,e431k:1.17,e308k:1.1,p439l:0.97,t306n:0.87,r460r:0.77,t495a:0.77,g442e:0.73,k294r:0.43,e316g:0.42,v260a:0.41,t243a:0.4,e450g:0.39,r473r:0.38 MT M 37 newly diagnosed CP none- imatinib first line 39959 4 Progression to BC at 4 mo N NA NA NA Q252H 30%,Y253H 15%,E255K 20%,T315I 30% 3